newsfilter
← Latest News
GlobeNewswire·

AEON Biopharma Reports Positive and Robust Biosimilarity Results: Identical Amino Acid Sequence and Highly Similar Functional Analysis Data

  • AEON Biopharma confirmed 100% amino acid sequence identity between ABP-450 & BOTOX® with 93%-99% sequence coverage across five proteins & no amino acid differences found in over 3,400 peptides analyzed.
  • Functional assays by Daewoong Pharmaceutical demonstrated strong similarity in potency, composition, & enzymatic activity between ABP-450 & BOTOX®.
  • ABP-450 showed highly similar potency to BOTOX® across LD 50 & cell-based potency assays, while ELISA confirmed comparable vial-to-vial active ingredient content.
  • The product is manufactured at commercial scale in an FDA-, EMA-, & Health Canada-inspected facility by Daewoong Pharmaceutical.
  • ABP-450 is the same complex marketed as Jeuveau® for aesthetic indications & is approved in 69 countries globally.
  • AEON submitted its analytical package to the FDA ahead of a scheduled Biosimilar Biological Product Development Type 2a meeting on November 19, 2025.
  • The company aims to achieve full-label U.S. market entry for ABP-450 as the first biosimilar to BOTOX® for therapeutic indications in a market exceeding $3 billion annually.